Mazdutide

Overview

Mazdutide is a dual GLP-1 / glucagon receptor agonist licensed from Eli Lilly to Innovent Biologics for Greater China. Approved by China's NMPA in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes; NOT FDA-approved in the US.

Mechanism of Action

Co-agonism of GLP-1R and GCGR produces additive metabolic effects — GLP-1 suppresses appetite and slows gastric emptying while glucagon agonism increases energy expenditure and mobilizes hepatic fat.

Research Summary

Phase 3 GLORY-1 (Ji et al., NEJM 2025) in 610 Chinese adults with obesity/overweight reported mean weight loss of ~11.0% (4 mg) and ~14.0% (6 mg) vs +0.3% placebo at 48 weeks. Additional Phase 3 programs (GLORY-2 obesity, DREAMS-1/2/3 T2DM) supported the NMPA approvals; a 9 mg supplementary application for moderate-to-severe obesity is under NMPA review.

Vendors selling Mazdutide

Scored vendors carrying Mazdutide, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• Nausea
• Vomiting
• Diarrhea
• Decreased appetite

Compare Mazdutide with Others

Research References

• Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1; Ji L et al., NEJM) (2025)
• Mazdutide: First Approval (Shirley M, Drugs) (2025)
• Innovent Announces Mazdutide Received Approval from China's NMPA for Chronic Weight Management (2025)

Frequently asked questions

Has Mazdutide been independently lab-tested?

Disclosed Labs has collected 8 Certificates of Analysis (COA) for Mazdutide from 4 independent testing labs. 5 vendors have submitted material for testing. Products average 99.7% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/mazdutide/testing.

What is the average purity of Mazdutide on the market?

Based on 8 COAs analyzed by Disclosed Labs, Mazdutide products average 99.7% (±0.3%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/mazdutide/coas.

Where can researchers source Mazdutide?

3 vendors with Disclosed Labs trust grades currently list Mazdutide, including Optima Supply, Hydro Research Peptides, zztai Peptide Ltd. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/mazdutide.

How does Mazdutide work?

Co-agonism of GLP-1R and GCGR produces additive metabolic effects — GLP-1 suppresses appetite and slows gastric emptying while glucagon agonism increases energy expenditure and mobilizes hepatic fat.

What does the research say about Mazdutide?

Phase 3 GLORY-1 (Ji et al., NEJM 2025) in 610 Chinese adults with obesity/overweight reported mean weight loss of ~11.0% (4 mg) and ~14.0% (6 mg) vs +0.3% placebo at 48 weeks. Additional Phase 3 programs (GLORY-2 obesity, DREAMS-1/2/3 T2DM) supported the NMPA approvals; a 9 mg supplementary application for moderate-to-severe obesity is under NMPA review.